Page 104 - Read Online

Falconer et al. MT-MMPs in prostate cancer

Jason Webber (Cardiff University) for organising the 13. Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix
inaugural Prostate Cancer &Tumor Microenvironment metalloproteinase is regulated by sp1 through the differential
workshop (Cardiff, January 2017), which provided the activation of AKT, JNK, and ERK pathways in human prostate tumor
cells. Neoplasia 2007;9:406-17.
catalyst for writing this review. 14. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate
cancer progression into androgen independency is associated with
Authors’ contributions alterations in cell adhesion and invasivity. Prostate 2006;66:1631-40.
R.A. Falconer and P.M. Loadman contributed equally 15. Gustavsson H, Welen K, Damber JE. Transition of an androgen-
to writing this review. dependent human prostate cancer cell line into an androgen-
independent subline is associated with increased angiogenesis.
Prostate 2005;62:364-73.
Financial support and sponsorship 16. Coulson-Thomas VJ, Gesteira TF, Coulson-Thomas YM, Vicente
None. CM, Tersariol IL, Nader HB, Toma L. Fibroblast and prostate tumor
cell cross-talk: fibroblast differentiation, TGF-beta, and extracellular
Conflicts of interest matrix down-regulation. Exp Cell Res 2010;316:3207-26.
RAF and PML declare that they are founding 17. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. Membrane-type-1 matrix
shareholders of Incanthera Ltd. metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of
matrix proteinase 2 in prostate cancer: identification of patients with
Patient consent poor prognosis by immunohistochemistry. Hum Pathol 2008;39:731-
9.
Not applicable. 18. Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX,
Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L.
Ethics approval Molecular genetic alterations in the laser-capture-microdissected
Not applicable. stroma adjacent to bladder carcinoma. Cancer 2003;98:1830-6.
19. Neuhaus J, Schiffer E, Mannello F, Horn LC, Ganzer R, Stolzenburg
JU. Protease expression levels in prostate cancer tissue can explain
REFERENCES prostate cancer-associated seminal biomarkers-an explorative concept
study. Int J Mol Sci 2017;18:E976.
20. Cardillo MR, Di Silverio F, Gentile V. Quantitative
1. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix
metalloproteinases in cancer progression and their pharmacological immunohistochemical and in situ hybridization analysis of
metalloproteinases in prostate cancer. Anticancer Res 2006;26:973-
targeting. FEBS J 2011;278:16-27.
82.
2. Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix 21. Reis ST, Viana NI, Iscaife A, Pontes-Junior J, Dip N, Antunes AA,
metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904-27.
3. Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug Guimaraes VR, Santana I, Nahas WC, Srougi M, Leite KR. Loss
of TIMP-1 immune expression and tumor recurrence in localized
development. Theranostics 2012;2:156-78. prostate cancer. Int Braz J Urol 2015;41:1088-95.
4. Law B, Tung CH. Proteolysis: a biological process adapted in drug 22. Arpino V, Brock M, Gill SE. The role of TIMPs in regulation of
delivery, therapy, and imaging. Bioconjug Chem 2009;20:1683-95. extracellular matrix proteolysis. Matrix Biol 2015;44-46:247-54.
5. Atkinson JM, Siller CS, Gill JH. Tumour endoproteases: the cutting 23. Reis ST, Antunes AA, Pontes-Junior J, Sousa-Canavez JM,
edge of cancer drug delivery? Br J Pharmacol 2008;153:1344-52. Dall’Oglio MF, Piantino CB, Cruz JA, Morais DR, Srougi M, Leite
6. Itoh Y. Membrane-type matrix metalloproteinases: their functions and KR. Underexpression of MMP-2 and its regulators, TIMP2, MT1-
regulations. Matrix Biol 2015;44-46:207-23. MMP and IL-8, is associated with prostate cancer. Int Braz J Urol
7. Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix 2012;38:167-74.
metalloproteinases and their natural inhibitors in prostate cancer 24. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD,
progression. Cancers 2014;6:1298-327. Fridman R, Sakr W, Grignon DJ, Cher ML. Membrane type 1-matrix
8. Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ. Characterization metalloproteinase (MT1-MMP) and MMP-2 immunolocalization
of expression of matrix metalloproteinases and tissue inhibitors of in human prostate: change in cellular localization associated with
metalloproteinases in prostate cancer cell lines. Prostate Cancer high-grade prostatic intraepithelial neoplasia. Clin Cancer Res
Prostatic Dis 2003;6:15-26. 1999;5:4105-10.
9. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K. Establishment of a 25. Sroka IC, McDaniel K, Nagle RB, Bowden GT. Differential
new prostatic carcinoma cell line (TSU-Pr1). J Urol 1987;137:1304-6. localization of MT1-MMP in human prostate cancer tissue: role of
10. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse IGF-1R in MT1-MMP expression. Prostate 2008;68:463-76.
H, Saiki I. Expression of membrane-type 1 matrix metalloproteinase 26. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan
(MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173- A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards
9. DR. Identification of degradome components associated with prostate
11. Jung M, Romer A, Keyszer G, Lein M, Kristiansen G, Schnorr D, cancer progression by expression analysis of human prostatic tissues.
Loening SA, Jung K. mRNA expression of the five membrane-type Br J Cancer 2005;92:2171-80.
matrix metalloproteinases MT1-MT5 in human prostatic cell lines and 27. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases:
their down-regulation in human malignant prostatic tissue. Prostate regulators of the tumor microenvironment. Cell 2010;141:52-67.
2003;55:89-98. 28. Sounni NE, Paye A, Host L, Noel A. MT-MMPS as regulators of vessel
12. Delassus GS, Cho H, Hoang S, Eliceiri GL. Many new down- and stability associated with angiogenesis. Front Pharmacol 2011;2:111.
up-regulatory signaling pathways, from known cancer progression 29. Larue L, Bellacosa A. Epithelial-mesenchymal transition in
suppressors to matrix metalloproteinases, differ widely in cells of development and cancer: role of phosphatidylinositol 3’ kinase/AKT
various cancers. J Cell Physiol 2010;224:549-58. pathways. Oncogene 2005;24:7443-54.
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017 325